Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Johnson & Johnson

Dividend ETFs are popular with income-focused investors, but some stand out more than others. Using TipRanks’ High Dividend Yield ETFs tool, we ide...

3 Dividend ETFs Paying 8%+ Passive Income

Insiders have been trading these 5 stocks: (($GOOG)), (($INTC)), (($MU)), (($JNJ)) and (($ADBE)). Here is a breakdown of their recent trades and th...

Alphabet, Intel, Micron, J&J, Adobe Insider Moves

Analysts are intrested in these 5 stocks: ( ($COIN) ), ( ($JNJ) ), ( ($PYPL) ), ( ($RTX) ) and ( ($PINS) ). Here is a breakdown of their recent


Coinbase, JNJ, PayPal, RTX, Pinterest Trending With Analysts

Johnson & Johnson ($JNJ) CEO Joaquin Duato has sold a major block of company stock just days after the healthcare giant reported mixed fourth-quart...

Johnson & Johnson (JNJ) CEO Dumps $22M in Stock Post Q4 Results. Should Investors Worry?

Johnson & Johnson ($JNJ) has delivered a strong run for investors, with the stock up 0.7% over the past week, 5.9% over the last month, and an impr...

Johnson & Johnson Trending as Analysts Stick With Buy

The TipRanks AI Analyst tool scans analyst ratings, price targets, and market trends to highlight stocks with strong upside potential. Using TipRan...

Top 3 Stocks to Watch Right Now, According to AI Analyst, 1/23/2026

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Medtronic (MDT – Research Report), Outlook Therape...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), Outlook Therapeutics (OTLK) and Johnson & Johnson (JNJ)

Johnson & Johnson (($JNJ)) has held its Q4 earnings call. Read on for the main highlights of the call. Johnson & Johnson Earnings Call Signals Port...

Johnson & Johnson Projects Strong Growth Beyond STELARA

Johnson & Johnson ($JNJ) shares fell 1.6% in premarket trading despite reporting strong Q4 and full-year 2025 results. The company posted Q4 revenu...

JNJ Earnings: Johnson & Johnson Stock Falls despite Q4 Revenue Beat

U.S. markets are reopening after a holiday, as investors return to trading following developments that emerged while markets were closed. With no t...

4 Things Investors Are Watching as Markets Reopen After the Long Weekend

This week, several major companies will be reporting earnings. Among them are Intel (INTC), Netflix (NFLX), Johnson & Johnson (JNJ), GE Aerospace (...

Options Volatility and Implied Earnings Moves This Week, January 20 – January 23, 2026

Johnson & Johnson ($JNJ) is scheduled to release its fourth-quarter fiscal 2025 results before the market opens on Wednesday, January 21. Analysts ...

Is Johnson & Johnson (JNJ) Stock a Buy Ahead of Q4 Earnings?

U.S. stocks finished the week essentially flat as a semiconductor-led bid was offset by softer bank performance and a steady drumbeat of policy hea...

The Week That Was, The Week Ahead: Macro and Markets, Jan. 18

In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Johnson & Johnson, with a price target of $230.00. According to ...

Scotiabank Sticks to Its Buy Rating for Johnson & Johnson (JNJ)

Johnson & Johnson ($JNJ) reached a significant agreement with the Trump administration to lower drug prices for Americans while securing exemptions...

Johnson & Johnson Wins Tariff Relief from Trump in a Drug Pricing Deal

In a report released on January 7, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Johnson & Johnson, with a price target of $240.0...

RBC Capital Reaffirms Their Buy Rating on Johnson & Johnson (JNJ)

The race for obesity-drug market share was one key highlight for Big Pharma in 2025. However, data shows the Big Pharma rally seen in 2025 is more ...

LLY, JNJ, PFE: Big Pharma’s 2025 Comeback Is Bigger Than the Obesity Craze

Shares in biotech firm Apogee Therapeutics ($APGE) sank about 5% early Tuesday despite reporting “positive” results from its early-stage human tria...

Apogee Therapeutics Stock (APGE) Plunges despite ‘Positive’ Asthma Drug Trial

Scotiabank analyst Louise Chen maintained a Buy rating on Johnson & Johnson today and set a price target of $230.00. Chen covers the Healthcare sec...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	JNJ	$234.82	+1.76%	5.70M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	JNJ	$234.82	+1.8%	5.70M
3
4
5
6

JNJ

JNJ

No Data Available

Get Johnson & Johnson Data in Excel

Get Johnson & Johnson Data in Excel